论文部分内容阅读
目的:研究扶正升血煎剂同步化疗治疗食管癌的临床疗效及预后生存分析。方法:选取本院在2011年1月—2013年2月收治的100例食管癌患者,将患者按照入院时间顺序分成两组,对照组采用化疗治疗;观察组在对照组的基础上加用扶正升血煎剂治疗,观察两组患者的近期治疗疗效,随访3年观察两组患者预后生存情况及期间不良反应发生情况。结果:观察组治疗总有效率(60.0%)明显高于对照组(32.0%)(P<0.05);治疗后观察组患者出现的血小板下降、骨髓抑制、胃肠道反应、白细胞下降等不良反应情况明显低于对照组(P<0.05);治疗后,观察组生活质量提高程度明显高于对照组(P<0.05);对所有患者随访3年,期间观察组1年生存率明显高于对照组(P<0.05);观察组2年生存率明显高于对照组(P<0.05);两组患者3年生存率比较无差异(P>0.05),但观察组存活人数多于对照组。结论:采用扶正升血煎剂同步化疗治疗食管癌,明显提高了临床治疗疗效、生活质量及患者的预后生存率,并且扶正升血煎剂无明显毒副作用,值得在临床上推广使用。
Objective: To study the clinical efficacy and prognosis of Fuzheng Shengxue decoction with concurrent chemotherapy in the treatment of esophageal cancer. Methods: A total of 100 patients with esophageal cancer admitted to our hospital from January 2011 to February 2013 were enrolled. Patients were divided into two groups according to the order of admission, while the control group was treated with chemotherapy. In the observation group, Fuzheng Ascites decoction treatment, the two groups of patients with short-term efficacy of treatment, followed up for 3 years to observe the prognosis of patients in two groups and the occurrence of adverse reactions during the period. Results: The total effective rate (60.0%) in observation group was significantly higher than that in control group (32.0%) (P <0.05). After treatment, adverse reactions such as thrombocytopenia, myelosuppression, gastrointestinal reaction and leukopenia occurred in observation group (P <0.05). After treatment, the quality of life of the observation group was significantly higher than that of the control group (P <0.05). All the patients were followed up for 3 years. The 1-year survival rate of the observation group was significantly higher than that of the control group (P <0.05). The 2-year survival rate in the observation group was significantly higher than that in the control group (P <0.05). There was no difference in the 3-year survival rate between the two groups (P> 0.05), but the survival rate in the observation group was more than that in the control group. Conclusions: The treatment of esophageal cancer with Fuzheng Shengxue decoction synchronous chemotherapy significantly improves clinical curative effect, quality of life and prognosis survival rate of patients, and Fuzheng Shengxue decoction has no obvious side effects and is worth popularizing in clinic.